ID   NCC-SS2-C1
AC   CVCL_VE84
SY   NCCSS2C1
DR   DepMap; ACH-002790
DR   Wikidata; Q54907634
RX   PubMed=29626278;
WW   https://en.cellline.jp/product/ncc-ss2-c1/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: NCC sarcoma cell line panel.
CC   Population: Japanese.
CC   Senescence: It is possible that this cell line is not immortal and has a finite life span (personal communication of Kondo T.).
CC   Doubling time: 52 hours (PubMed=29626278).
CC   Sequence variation: Gene fusion; HGNC; 11340; SS18 + HGNC; 11336; SSX2; Name(s)=SS18-SSX2 (PubMed=29626278).
CC   Omics: Deep proteome analysis.
ST   Source(s): PubMed=29626278
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 8,11
ST   D16S539: 10,13
ST   D21S11: 29,30
ST   D5S818: 11,12
ST   D7S820: 12
ST   TH01: 7,9
ST   TPOX: 8,9
ST   vWA: 17,18
DI   NCIt; C3400; Synovial sarcoma
DI   ORDO; Orphanet_3273; Synovial sarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   43Y
CA   Cancer cell line
DT   Created: 14-05-18; Last updated: 30-01-24; Version: 10
//
RX   PubMed=29626278; DOI=10.1007/s11626-018-0237-7;
RA   Oyama R., Kito F., Sakumoto M., Shiozawa K., Toki S., Endo M.,
RA   Yoshida A., Kawai A., Kondo T.;
RT   "Establishment and proteomic characterization of a novel synovial
RT   sarcoma cell line, NCC-SS2-C1.";
RL   In Vitro Cell. Dev. Biol. Anim. 54:392-399(2018).
//